Oral hypoglycemic therapy: understanding the mechanisms of transplacental transfer
- PMID: 20064105
- DOI: 10.3109/14767050903550881
Oral hypoglycemic therapy: understanding the mechanisms of transplacental transfer
Abstract
The current trend towards an increase in the rate of Type 2 diabetes in women of childbearing age will inevitably result in an increasing number of women requiring hypoglycemic therapy throughout pregnancy. For patients with Type 2 diabetes or gestational diabetes, oral hypoglycemic agents (OHAs) represent an attractive alternative to insulin therapy. However, there exists some apprehension regarding the use of OHAs during pregnancy. Although the current accepted understanding is that most drugs administered during pregnancy can permeate the placental barrier, there is sufficient evidence to suggest that the placenta is capable of limiting fetal exposure to drugs. In particular, large sets of data on the transplacental transfer and clinical use of glyburide in pregnancy have suggested that glyburide may be a safe alternative to insulin therapy. Glyburide's limited fetal transfer has been attributed to its high protein binding, rapid clearance rate and the role of placental efflux transporters such as the breast cancer resistance protein. However, there are a number of maternal, placental and fetal factors that may alter the transplacental passage of drugs used in pregnancy. Therefore, it is essential that OHAs are further investigated to determine their safety with confidence and provide better treatment options for diabetes in pregnancy.
Similar articles
-
Oral hypoglycemic agents in pregnancy: their time has come.J Matern Fetal Neonatal Med. 2002 Dec;12(6):376-83. doi: 10.1080/jmf.12.6.376.383. J Matern Fetal Neonatal Med. 2002. PMID: 12683647 Review.
-
Investigating the potential role of multi-drug resistance protein (MRP) transporters in fetal to maternal glyburide efflux in the human placenta.J Obstet Gynaecol. 2008 Jul;28(5):485-9. doi: 10.1080/01443610802091420. J Obstet Gynaecol. 2008. PMID: 18850420
-
Effect of human serum albumin on transplacental transfer of glyburide.Biochem Pharmacol. 2006 Aug 28;72(5):632-9. doi: 10.1016/j.bcp.2006.05.019. Epub 2006 Jul 7. Biochem Pharmacol. 2006. PMID: 16828060
-
Perfusion studies of glyburide transfer across the human placenta: implications for fetal safety.Am J Obstet Gynecol. 2006 Jul;195(1):270-4. doi: 10.1016/j.ajog.2005.12.005. Epub 2006 Mar 30. Am J Obstet Gynecol. 2006. PMID: 16579925
-
Oral hypoglycemic agents for gestational diabetes mellitus?Expert Opin Drug Saf. 2011 Mar;10(2):227-38. doi: 10.1517/14740338.2011.521740. Epub 2011 Jan 6. Expert Opin Drug Saf. 2011. PMID: 21210750 Review.
Cited by
-
Comparative impact of pharmacological treatments for gestational diabetes on neonatal anthropometry independent of maternal glycaemic control: A systematic review and meta-analysis.PLoS Med. 2020 May 22;17(5):e1003126. doi: 10.1371/journal.pmed.1003126. eCollection 2020 May. PLoS Med. 2020. PMID: 32442232 Free PMC article.
-
Fetus Exposure to Drugs and Chemicals: A Holistic Overview on the Assessment of Their Transport and Metabolism across the Human Placental Barrier.Diseases. 2024 Jun 1;12(6):114. doi: 10.3390/diseases12060114. Diseases. 2024. PMID: 38920546 Free PMC article. Review.
-
Predictors of metformin monotherapy failure in gestational diabetes mellitus.Endocr Connect. 2022 May 10;11(5):e210540. doi: 10.1530/EC-21-0540. Endocr Connect. 2022. PMID: 35521811 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical